Across the time periods, by 1-year post-op only 38% of high-risk patients and 29% of low-risk patients had undergone colonoscopy. In 2015, the first Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) consensus recommended that clinicians employ endoscopic remission, with the resolution of subclinical inflammation, as the primary treatment target for patients with inflammatory bowel disease (IBD) [[1]]. Abbreviations STRIDE Selecting therapeutic targets in inflammatory bowel disease consensus IBD Inflammatory bowel disease POCER Postoperative Crohn's endoscopic recurrence trial CD Crohn's disease FC Fecal calprotectin CRP C-reactive protein SPARC IBD Study of a prospective adult research cohort with IBD Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. [Extracted from the article]